JUN 27, 2018 6:51 AM PDT

Potential Drug May 'Freeze' Cancer Cells

WRITTEN BY: Nouran Amin

New research study is bringing hope to cancer patients undergoing the early stages of the disease, published in the journal Nature Communications, the study examines a drug compound that can put a stop onto cancer motility.

When cancer cells spread to other regions of our body that is known as metastasis which is a hallmark for deciding a cancer patient's death.

“For the vast majority of cancer—breast, prostate, lung, colon, and others—if it is detected early when it is a little lump in that organ and it has not spread, you will live. And generally, if you find it late, after it has spread throughout your body, you will die,” explains study author, Raymond Bergan, “Movement is key: the difference is black and white, night and day. If cancer cells spread throughout your body, they will take your life. We can treat it, but it will take your life.”

Although awareness on cancer is high, research was only able to focus on therapies that can kill cancer cells with no current treatment known.

However, in 2011, Bergan and colleagues began a study with chemists to seek a drug that would primarily inhibit cancer motility. They found a compound known as KBU2046 that has the potential ability to exert effects on cell motility in multiple cancers.

The study was achieved by utilizing chemical synthesis approaches to identify compounds that could alter motility in tumor cells without debilitating side effects or toxicity.

“We started off with a chemical that stopped cells from moving, then we increasingly refined that chemical until it did a perfect job of stopping the cells with no side effects,” Bergan explained.

The goal for this drug is to ultimately mange cancer in the early stages before reaching the incurable phase. However, the study has yet to expand in human testing.

“Our eventual goal is to be able to say to a woman with breast cancer: here, take this pill and your cancer won’t spread throughout your body. The same thing for patients with prostate, lung, and colon cancer,” explains Bergan.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
NOV 24, 2020
Drug Discovery & Development
MMR Vaccine Shows Promise Against COVID-19
NOV 24, 2020
MMR Vaccine Shows Promise Against COVID-19
Researchers have found that a vaccine used for mumps, measles, and rubella (MMR) may be effective in protecting against ...
NOV 26, 2020
Drug Discovery & Development
Sestrin Increases the Lifespan of Fruit Flies
NOV 26, 2020
Sestrin Increases the Lifespan of Fruit Flies
Reduced food intake, known as dietary restriction, leads to a longer lifespan in many animals and can improve health in ...
Loading Comments...